文献速递乳腺癌

帕尼单抗联合新辅助化疗治疗初治HER2阴性炎性乳腺癌的安全性与疗效

Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.
PubMed 文献 · JAMA Oncol · 2018-01-01

该研究纳入40例初治HER2阴性炎性乳腺癌女性,接受帕尼单抗联合新辅助化疗,中位随访19.3个月。总体pCR率为28%(11/40,95%CI 15%-44%),三阴性亚组为42%(8/19,95%CI 20%-66%),激素受体阳性/HER2阴性亚组为14%(3/21,95%CI 3%-36%)。治疗期间10例因治疗相关毒性住院,无治疗相关死亡。

要点

  • 帕尼单抗联合新辅助化疗在初治HER2阴性炎性乳腺癌中总体pCR率为28%。
  • 三阴性炎性乳腺癌亚组pCR率达42%,为目前报道最高。
  • 常见非血液学不良事件为皮疹,10例因治疗相关毒性住院。

核心结论

  • 帕尼单抗联合化疗在初治HER2阴性炎性乳腺癌中显示出疗效,三阴性亚组pCR率尤为突出。
  • 需要随机2期研究确定帕尼单抗在三阴性炎性乳腺癌中的作用并验证预测生物标志物。

研究设计与样本

  • 单臂研究,2010至2015年纳入初治HER2阴性炎性乳腺癌女性,接受帕尼单抗联合新辅助化疗。
  • 中位随访19.3个月,最终40例纳入分析,中位年龄57岁(范围23-68岁),29例(72%)为绝经后。
  • 主要终点为pCR率,次要终点为安全性,探索性目标为识别预测pCR的生物标志物。

主要发现

  • 总体pCR率为28%(11/40,95%CI 15%-44%)。
  • 三阴性炎性乳腺癌pCR率为42%(8/19,95%CI 20%-66%)。
  • 激素受体阳性/HER2阴性炎性乳腺癌pCR率为14%(3/21,95%CI 3%-36%)。
  • 治疗期间10例因治疗相关毒性住院,其中5例为中性粒细胞减少相关事件,无治疗相关死亡。
  • 最常见的非血液学不良事件为皮疹,探索性分析发现pEGFR表达和COX-2表达等潜在pCR预测因子。

关键数值与推荐

  • 帕尼单抗首剂2.5 mg/kg,随后4周期帕尼单抗2.5 mg/kg联合白蛋白紫杉醇100 mg/m2和卡铂每周给药。
  • 后续4周期氟尿嘧啶500 mg/m2、表柔比星100 mg/m2和环磷酰胺500 mg/m2每3周给药。

临床怎么用

  • 该方案可作为初治HER2阴性炎性乳腺癌,尤其是三阴性亚组的潜在新辅助治疗选择。
  • 治疗期间需密切监测皮疹和中性粒细胞减少等毒性,及时处理治疗相关住院事件。

局限性

  • 单臂设计,样本量有限(40例),无法直接比较帕尼单抗联合化疗与单纯化疗的疗效差异。
  • 随访时间较短(中位19.3个月),长期生存获益尚未明确。
  • 生物标志物分析为探索性,预测价值需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Combining conventional chemotherapy with targeted therapy has been proposed to improve the pathologic complete response (pCR) rate in patients with inflammatory breast cancer (IBC). Epidermal growth factor receptor (EGFR) expression is an independent predictor of low overall survival in patients with IBC. OBJECTIVE: To evaluate the safety and efficacy of the anti-EGFR antibody panitumumab plus neoadjuvant chemotherapy in patients with primary human epidermal growth factor receptor 2 (HER2)-negative IBC. DESIGN, SETTING, AND PARTICIPANTS: Women with primary HER2-negative IBC were enrolled from 2010 to 2015 and received panitumumab plus neoadjuvant chemotherapy. Median follow-up time was 19.3 months. Tumor tissues collected before and after the first dose of panitumumab were subjected to immunohistochemical staining and RNA sequencing analysis to identify biomarkers predictive of pCR. INTERVENTION: Patients received 1 dose of panitumumab (2.5 mg/kg) followed by 4 cycles of panitumumab (2.5 mg/kg), nab-paclitaxel (100 mg/m2), and carboplatin weekly and then 4 cycles of fluorouracil (500 mg/m2), epirubicin (100 mg/m2), and cyclophosphamide (500 mg/m2) every 3 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was pCR rate; the secondary end point was safety. The exploratory objective was to identify biomarkers predictive of pCR. RESULTS: Forty-seven patients were accrued; 7 were ineligible. The 40 enrolled women had a median age of 57 (range, 23-68) years; 29 (72%) were postmenopausal. Three patients did not complete therapy because of toxic effects (n = 2) or distant metastasis (n = 1). Nineteen patients had triple-negative and 21 had hormone receptor-positive IBC. The pCR and pCR rates were overall, 11 of 40 (28%; 95% CI, 15%-44%); triple-negative IBC, 8 of 19 (42%; 95% CI, 20%-66%); and hormone receptor-positive/HER2-negative IBC, 3 of 21 (14%; 95% CI, 3%-36%). During treatment with panitumumab, nab-paclitaxel, and carboplatin, 10 patients were hospitalized for treatment-related toxic effects, including 5 with neutropenia-related events. There were no treatment-related deaths. The most frequent nonhematologic adverse event was skin rash. Several potential predictors of pCR were identified, including pEGFR expression and COX-2 expression. CONCLUSIONS AND RELEVANCE: This combination of panitumumab and chemotherapy showed the highest pCR rate ever reported in triple-negative IBC. A randomized phase 2 study is ongoing to determine the role of panitumumab in patients with triple-negative IBC and to further validate predictive biomarkers. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01036087.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Matsuda N, Wang X, Lim B, et al. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018. PMID: 29879283. doi:10.1001/jamaoncol.2018.1436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。